 




<DOCTITLE>Importation of Controlled Substances; Notice of Application</DOCTITLE>



Pursuant to Section 1008 of the Controlled Substances Import and Export Act (21 U.S.C. 958(i)), the Attorney General
shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in Schedule
I or II and prior to issuing a regulation under Section 1002(a) authorizing the importation of such a substance, provide
manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing.

Therefore, in accordance with 1311.42 of Title 21, Code of Federal Regulations (CFR), notice is hereby given
that on October 27, 1994, The Binding Site, Inc., 5889 Oberlin Drive, Suite 101, San Diego, California 92121, made
application to the Drug Enforcement Administration to be registered as an importer of the basic classes of controlled
substances listed below:



<TABLE>





1Drug

1Schedule





Methaqualone (2565) 
I
Lysergic acid diethylamide (7315) 
I
Tetrahydrocannabinols (7370) 
I
3,4-Methylenedioxymetham- 
phetamine (7405) 
I
Normorphine (9313) 
I
Methamphetamine (1105) 
II
Amobarbital (2125) 
II
Secobarbital (2315) 
II
Benzoylecgonine (9180) 
II
Ethylmorphine (9190) 
II
Methadone intermediate (9254) 
II


</TABLE>



The firm plans to import the above listed substances in milligrams quantities for labelling with enzymes, fluorophores
and radioisotopes for immunoassays.

Any manufacturer holding, or applying for, registration as a bulk manufacturer of this basic class of controlled
substance may file written comments on or objections to the application described above and may, at the same time,
file a written request for a hearing on such application in accordance with 21 CFR 1301.54 in such form as prescribed
by 21 CFR 1316.47.

Any such comments, objections, or requests for a hearing may be addressed to the Deputy Assistant Administrator,
Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington,
DC 20537, Attention: DEA Federal Register Representative (CCR), and must be filed no later than January 5, 1995.

This procedure is to be conducted simultaneously with and independent of the procedures described in 21 CFR 1311.42
(b), (c), (d), (e), and (f). As noted in a previous notice at 40 FR 4374546 (September 23, 1975), all applicants
for registration to import a basic class of any controlled substance in Schedule I or II are and will continue to be required
to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration
that the requirements for such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1311.42 (a),
(b), (c), (d), (e), and (f) are satisfied.






Dated: November 23, 1994.



<SIGNER>
Gene R. Haislip,


</SIGNER>
<SIGNJOB>
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.


</SIGNJOB>
<FRFILING>
[FR Doc. 9429946 Filed 12594; 8:45 am]


</FRFILING>
<BILLING>
BILLING CODE 441009M
</BILLING>



